NEW YORK – Cue Health announced on Thursday that it has entered a distribution agreement for its COVID-19 molecular tests with Cardinal Health.
Under the agreement, healthcare professionals and other point-of-care users can purchase the Cue Health Monitoring System, the Cue COVID-19 test for professional use, and Cue COVID-19 Test Positive Control Swabs and Test Negative Control Swabs through Cardinal's laboratory distribution network.
In addition, the Cue test for home and over-the-counter use is available through Cardinal's network. Both the professional and home products will be available in packs of 10 tests, Cue said in a statement.
Financial and other terms of the deal were not disclosed.
Cue's home test received Emergency Use Authorization from the US Food and Drug Administration in March and was the first molecular test authorized by the FDA for home use without a prescription.
Cardinal Health distributes pharmaceuticals, manufactures and distributes medical and laboratory products, and provides performance and data solutions for healthcare facilities.